News | May 14, 2025
Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
EBITDA before special items decreases to €4.08 billion (7.4%)
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Scores highest PAT of Rs. 118 crore in FY25
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Gelhaus has a proven track record of driving business growth
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
This recertification of Company's OECD GLP is testimony to company's unwavering commitment to maintain international quality standards at the facility
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
